Efavirenz in an Obese HIV-Infected Patient – a Report and An In Vitro–In Vivo Extrapolation Model Indicate Risk of Underdosing
暂无分享,去创建一个
[1] J. Vaidyanathan,et al. Implications of Obesity for Drug Therapy: Limitations and Challenges , 2011, Clinical pharmacology and therapeutics.
[2] Darren L. Smith,et al. Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir , 2010, Antimicrobial Agents and Chemotherapy.
[3] Zeruesenay Desta,et al. Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation , 2010, Drug Metabolism and Disposition.
[4] L. Eberly,et al. Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic , 2010, PloS one.
[5] C. Guillemette,et al. Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine , 2009, Drug Metabolism and Disposition.
[6] A. Telenti,et al. Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction , 2008, Therapeutic drug monitoring.
[7] C. Leen,et al. Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication , 2008, Antiviral therapy.
[8] S. Urien,et al. Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy , 2008, Antimicrobial Agents and Chemotherapy.
[9] A. Telenti,et al. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[10] David A. Flockhart,et al. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[11] U. Hofmann,et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.
[12] A. Telenti,et al. Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .
[13] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.